Acquiring Company
Cellution Biologics
Acquired Company
WORQ
Roswell
MalaysiaManufacturingBiotechnologyHealth CareMedicalMedical DeviceDescription
Cellution Biologics has completed the acquisition of the SimpliDerm business from Elutia Inc. for US$8 million, marking its entry into the U.S. reconstructive surgery market. This acquisition adds a new surgical category to Cellution's portfolio while leveraging established relationships in the market. The deal may include additional transition and milestone payments over the next 18 months.
Don't miss Cellution Biologics's next move
Get an email the moment Cellution Biologics makes an acquisition, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
M&A Insights
Based on deal dataFrequently asked
Who acquired WORQ?
WORQ was acquired by Cellution Biologics, based in Roswell. The deal was reported on August 18, 2026. Cellution Biologics is focused on developing, manufacturing and commercializing advanced human tissue-based products for wound care, ocular repair, reconstructive surgery and other surgical applications. Cellution Biologics is privately held and operates in Manufacturing.
When did Cellution Biologics acquire WORQ?
Cellution Biologics's acquisition of WORQ was reported on August 18, 2026. Cellution Biologics has completed the acquisition of the SimpliDerm business from Elutia Inc. for US$8 million, marking its entry into the U.S. reconstructive surgery market. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does WORQ do?
Malaysia-based co-working space provider with a goal to expand its co-working space operations. It is privately held, and is based in Malaysia.